The Results: Diagnosis, Complete Picture, and the Path to pCR

November 14th, 2025. Seven days after that whirlwind of diagnostic tests. The MRI had been done. The biopsy results were in. All the pieces of the puzzle were finally on the table. Time to see the complete picture.

The Week Between

Those seven days between testing and results felt endless:

• November 7: The tests
• November 10: The MRI (more waiting in machines, more questions)
• November 12: Pathology results released
• November 14: This appointment - the full picture

The Pathology Results

The microscopic truth, revealed:

What It Is

Invasive Ductal Carcinoma (IDC), No Special Type

The most common type of breast cancer. “Invasive” means it’s grown beyond the milk ducts into surrounding tissue. “No special type” means it’s the standard variety - which is actually good because it’s the most studied and understood.

How Aggressive

Grade 3

The cancer cells are graded on how different they look from normal cells and how fast they’re dividing.

The specific score: 3+3+2

• Cell structure: 3 (quite different from normal)
• Cell organization: 3 (poorly organized)
• Cell division rate: 2 (moderate activity)
• Total: Grade 3 (high grade)

What this means: Fast-growing, aggressive cells. But here’s the paradox - fast-growing cancers tend to respond better to chemotherapy. These aggressive cells are actually more vulnerable to treatment.

The Critical Detail: Receptor Status

This is where the story gets more hopeful.

Test Results:

• ER (Estrogen Receptor): 0 - Negative
• PR (Progesterone Receptor): 0 - Negative
• HER2: 3+ - Strongly Positive

Why HER2-Positive Changes Everything

Twenty years ago, HER2-positive breast cancer was one of the most feared diagnoses. Today? It’s one of the most treatable.

What HER2 means: The cancer cells have too much HER2 protein on their surface. This protein acts like a growth signal, telling cells to multiply rapidly.

Why this is good news: Scientists have developed drugs that specifically target that HER2 protein. Drugs like Herceptin (trastuzumab) and Perjeta (pertuzumab) essentially block the growth signals, stopping cancer cells in their tracks.

The numbers: With modern HER2-targeted therapy plus chemotherapy, 70-80% of people achieve complete response - meaning no remaining cancer cells at surgery.

Lymph Node Involvement

The biopsy of the axillary lymph node came back positive - cancer cells confirmed in the lymph node. Cancer cells had traveled from the breast to at least one lymph node in the underarm (axilla).

This was expected based on the imaging, but confirmation still stings. However, it doesn’t change the treatment approach - NACT was already the plan.

The Silver Linings in the Pathology Report

Not everything in the report was concerning:

• Brisk lymphocytic response - the immune system had noticed the cancer and was mounting a defense
• No vascular invasion - cancer hadn’t entered blood vessels
• No DCIS - no pre-cancerous changes elsewhere

The Imaging: Complete Disease Mapping

Mammogram (November 7)

• Primary mass: 3 cm, spiculated appearance
• Location: Lower outer right breast, 4 cm from nipple
• Classification: M5 (highly suggestive of malignancy)
• Good news: Not involving skin or chest wall

Ultrasound (November 7)

• Primary mass: 22 x 17 x 19 mm at 7 o’clock position
• Lymph nodes: 5-7 pathological nodes identified
• Largest node: 22 mm
• Classification: U5 for breast and axilla

MRI (November 10) - The Most Detailed View

The MRI with contrast provided the complete map:

Primary Tumour:

• Size: 24 x 25 x 20 mm (about 25mm total)
• Location: Lower central, slightly outer right breast
• Hydromarker visible - the tiny titanium clip from biopsy day, marking the spot

Possible Satellite Lesion:

• Small 5mm focus, 10mm in front of the main tumour
• Similar enhancement pattern
• If confirmed malignant: Total disease extent would be 35mm
• Too close to main tumour for separate biopsy

Lymph Nodes:

• At least 2 confirmed pathological nodes in right axilla (up to 11mm)
• Additional 8mm indeterminate node higher up
• Abnormal internal architecture

Left Breast:

• Two tiny foci (5mm and 7mm) with low suspicion
• Need follow-up but unlikely to be concerning

Classification: MR6 (biopsy-proven malignancy)

The Consultation: The Complete Picture

The surgeon had all the pieces now. Imaging from three different modalities. Pathology confirmation. Time to draw the roadmap.

He sketched it out by hand on the report - a visual explanation of what comes next.

The Strategy: NACT

NACT = Neoadjuvant Chemotherapy

“Neoadjuvant” means treatment given before surgery (as opposed to “adjuvant,” which is after surgery).

Why chemotherapy first?

1. Shrink the tumour - make surgery less extensive
2. Treat systemic disease early - address any microscopic cancer cells that might be elsewhere
3. Test in real-time - see how well the cancer responds to treatment
4. Improve surgical outcomes - potentially allow for less extensive surgery
5. For HER2-positive disease - includes targeted therapy alongside chemo

The Goal: pCR

pCR = Pathological Complete Response

This is the target. The finish line. The best possible outcome.

What it means: After completing chemotherapy and targeted therapy, when the surgeon removes the remaining tissue and it’s examined under a microscope, no cancer cells are found - not in the breast, not in the lymph nodes. Complete response.

Why it matters:

• Best long-term prognosis
• Dramatically reduces recurrence risk
• Associated with excellent survival rates
• For HER2-positive cancer, it’s genuinely achievable

The realistic hope: With modern dual HER2-targeted therapy (Herceptin + Perjeta) plus chemotherapy, 70-80% of people with HER2-positive breast cancer achieve pCR.

That’s not a small chance. That’s a real, achievable goal.

Disease Summary: What We’re Facing

Primary Disease:

• 25mm invasive ductal carcinoma (possibly up to 35mm with satellite)
• Grade 3 (high grade, fast-growing)
• HER2-positive (targetable with modern drugs)
• ER and PR negative

Lymph Nodes:

• Multiple right axillary nodes involved
• Biopsy-proven lymph node involvement
• Largest confirmed node: 22mm

Stage:

• Clinical staging to be finalized by oncology
• Node-positive disease
• Likely Stage II or III (exact staging pending)

The Emotional Truth

Hearing “invasive,” “Grade 3,” “node-positive,” and “cancer spread” in the same conversation is overwhelming. These are scary words.

But hearing “HER2-positive,” “targeted therapy,” “pCR rates of 70-80%,” and “highly treatable” alongside them provides the lifeline.

This isn’t the news anyone wants. But if you’re going to get a breast cancer diagnosis, HER2-positive in 2025 is a very different story than it would have been even 15 years ago.

What Happens Next

The surgeon’s role in the diagnostic phase is complete. He’s mapped the territory, confirmed the diagnosis, outlined the strategy.

Now comes the specialist: Medical Oncology.

• Detailed treatment protocol development
• Specific drug combinations and doses
• Treatment schedule and timeline
• Side effect management
• Support services

Next appointment: Oncology consultation scheduled for November 25th, 2025.

Holding Onto Hope

The surgeon’s hand-drawn sketch showed:

• Where we are now
• Where we’re going (NACT)
• What we’re aiming for (pCR)

It’s a roadmap through difficult terrain, but it is a map. There’s a path. There are guides. There are tools specifically designed for this type of cancer.

The facts without fear:

• HER2-positive = treatable with targeted drugs
• Grade 3 = responds well to chemotherapy
• NACT = shrink it first, surgery after
• pCR = the achievable goal
• Modern medicine has transformed HER2-positive outcomes

The journey is daunting. But the destination - pCR - is genuinely possible.

---

Date: November 14, 2025
Diagnosis: Invasive Ductal Carcinoma, Grade 3, HER2-positive, ER/PR-negative, node-positive
Treatment Strategy: NACT (Neoadjuvant Chemotherapy with HER2-targeted therapy)
Goal: pCR (Pathological Complete Response)
Next Step: Medical Oncology consultation, November 25, 2025